Role of Kappa Opioid Receptors in Symptoms of Schizophrenia: What Is the Neurobiology?
- 1 October 2019
- journal article
- editorial
- Published by Elsevier in Biological Psychiatry
- Vol. 86 (7) , 494-496
Abstract
No abstract availableFunding Information
- National Institutes of Health
This publication has 10 references indexed in Scilit:
- The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the EvidenceBiological Psychiatry, 2019
- Targeting opioid dysregulation in depression for the development of novel therapeuticsPharmacology & Therapeutics, 2019
- Aberrant salience network functional connectivity in auditory verbal hallucinations: a first episode psychosis sampleTranslational Psychiatry, 2018
- Pathway- and Cell-Specific Kappa-Opioid Receptor Modulation of Excitation-Inhibition Balance Differentially Gates D1 and D2 Accumbens Neuron ActivityNeuron, 2017
- Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical TrialsDepression and Anxiety, 2016
- Attention: the claustrumTrends in Neurosciences, 2015
- Prefrontal Cortical Kappa-Opioid Receptor Modulation of Local Neurotransmission and Conditioned Place AversionNeuropsychopharmacology, 2013
- Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in ratsPsychopharmacology, 2010
- Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonistProceedings of the National Academy of Sciences, 2002
- Dynorphin Is a Specific Endogenous Ligand of the κ Opioid ReceptorScience, 1982